A phase I dose escalation and pharmacokinetic study of oral clofarabine administered daily for 5 days in adult patients with refractory solid tumors.

Trial Profile

A phase I dose escalation and pharmacokinetic study of oral clofarabine administered daily for 5 days in adult patients with refractory solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Sep 2008 Actual patient number (24) added as reported by ClinicalTrials.gov.
    • 17 Sep 2008 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 22 Feb 2006 Trial identifier CLO152A2 changed to CLO152 reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top